-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
Research & Education
A GLP-1 weight loss plateau is a period when the scale changes slowly or remains relatively stable after an earlier decline. Long-term trial curves show that this pattern is common at the group level, although timing and magnitude vary.
As body mass decreases, energy requirements and several adaptive signals change. Appetite, energy expenditure, adherence, activity and medication tolerability may all influence the trajectory. A flat short-term reading can also reflect ordinary fluid and measurement variation.
In STEP 5, average semaglutide-associated weight reduction was maintained through 104 weeks, while the group curve became less steep later in treatment. SELECT also provided multi-year data showing sustained average weight change in its specific population. A plateau therefore does not automatically mean that all treatment effects have disappeared.
Participants enter trials with different characteristics and follow structured protocols. Some discontinue treatment, some do not reach the average result and others exceed it. Clinicians assess response, health status, tolerability and approved labeling together.
Useful topics include whether the apparent plateau is long enough to be meaningful, whether other medicines or medical conditions may matter, and whether nutrition, strength, sleep or activity need review. This is an evaluation—not a reason for self-directed dose escalation.
No. A plateau means relative stability; regain means an upward trend. Both require enough measurements over time to distinguish them from day-to-day noise.
No. Weight is only one outcome, and a stable phase can occur during sustained treatment.
Approved labeling warns against combining semaglutide-containing products or using them with another GLP-1 receptor agonist. Medication combinations require prescriber review.
See the separate evidence review on treatment withdrawal and weight regain.
